title: Advances in the treatment of pancreatic neuroendocrine tumours.
abstract: Pancreatic neuroendocrine tumours (pNETs) are relatively rare and generally felt to follow an indolent course. But poorly differentiated tumours can behave aggressively with 5-year survival ranging from 31% to 48%. Recent data suggest that patients with pNETs may derive benefit from treatment targeting the molecular changes expressed in this tumour group. This article describes advances in the treatment of unresectable pNETs that have led to a doubling of progression free survival.
authors.affiliation: Department of Surgery and Cancer, Imperial College, London W12 0NN, UK.
authors.forename: F
authors.initials: F
authors.lastname: Gao
authors.forename: E-E P
authors.initials: EE
authors.lastname: Visvardis
authors.forename: A
authors.initials: A
authors.lastname: Sita-Lumsden
authors.forename: J
authors.initials: J
authors.lastname: Waxman
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D018572:Disease-Free Survival; D000068338:Everolimus; D006801:Humans; D007211:Indoles / Q000494:pharmacology / Q000627:therapeutic use; D018358:Neuroendocrine Tumors / Q000188:drug therapy*; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D011758:Pyrroles / Q000494:pharmacology / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D020123:Sirolimus / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D000077210:Sunitinib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000068338:Everolimus; D000077210:Sunitinib; D020123:Sirolimus